Diagnosis of pheochromocytoma and paraganglioma

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

There has been a dramatic evolution in both the clinical presentation and the methods used to diagnose pheochromocytoma and paraganglioma (PPGL) over the past nine decades. Due to the advances in biochemical testing and cross-sectional computed imaging, we have progressed from prior to 1970 when 90% of patients with PPGL were detected because of symptoms (paroxysms or hypertension) to 2018 when 60% of patients with PPGL are diagnosed due to an incidental discovery on cross-sectional imaging done for other reasons. Thus, the clinician should recognize the imaging phenotype typical for a pheochromocytoma. The differential diagnosis for those patients who present with symptoms spans the field of medicine. Biochemical case detection testing relies on measurement of fractionated metanephrines and catecholamines by tandem mass spectrometry or high-pressure liquid chromatography. The clinician should assess the relative likelihood of pheochromocytoma in each patient. Decisions for the type of test performed may be subject to clinical availability, cost, clinical experience of the ordering physician, and the local laboratory. However, it is key to understand the medications and clinical situations that may cause false-positive biochemical testing.

Original languageEnglish (US)
Title of host publicationContemporary Endocrinology
PublisherHumana Press Inc.
Pages99-111
Number of pages13
DOIs
StatePublished - Jan 1 2018

Publication series

NameContemporary Endocrinology
ISSN (Print)2523-3785
ISSN (Electronic)2523-3793

Fingerprint

Paraganglioma
Pheochromocytoma
Metanephrine
Incidental Findings
Tandem Mass Spectrometry
Catecholamines
Differential Diagnosis
High Pressure Liquid Chromatography
Medicine
Hypertension
Physicians
Phenotype
Costs and Cost Analysis

Keywords

  • Catecholamines
  • Metanephrines
  • Paraganglioma
  • Pheochromocytoma

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Young, W. F. (2018). Diagnosis of pheochromocytoma and paraganglioma. In Contemporary Endocrinology (pp. 99-111). (Contemporary Endocrinology). Humana Press Inc.. https://doi.org/10.1007/978-3-319-77048-2_6

Diagnosis of pheochromocytoma and paraganglioma. / Young, William Francis.

Contemporary Endocrinology. Humana Press Inc., 2018. p. 99-111 (Contemporary Endocrinology).

Research output: Chapter in Book/Report/Conference proceedingChapter

Young, WF 2018, Diagnosis of pheochromocytoma and paraganglioma. in Contemporary Endocrinology. Contemporary Endocrinology, Humana Press Inc., pp. 99-111. https://doi.org/10.1007/978-3-319-77048-2_6
Young WF. Diagnosis of pheochromocytoma and paraganglioma. In Contemporary Endocrinology. Humana Press Inc. 2018. p. 99-111. (Contemporary Endocrinology). https://doi.org/10.1007/978-3-319-77048-2_6
Young, William Francis. / Diagnosis of pheochromocytoma and paraganglioma. Contemporary Endocrinology. Humana Press Inc., 2018. pp. 99-111 (Contemporary Endocrinology).
@inbook{6540d8d8c49c4cc085a50f43fb9b5cb0,
title = "Diagnosis of pheochromocytoma and paraganglioma",
abstract = "There has been a dramatic evolution in both the clinical presentation and the methods used to diagnose pheochromocytoma and paraganglioma (PPGL) over the past nine decades. Due to the advances in biochemical testing and cross-sectional computed imaging, we have progressed from prior to 1970 when 90{\%} of patients with PPGL were detected because of symptoms (paroxysms or hypertension) to 2018 when 60{\%} of patients with PPGL are diagnosed due to an incidental discovery on cross-sectional imaging done for other reasons. Thus, the clinician should recognize the imaging phenotype typical for a pheochromocytoma. The differential diagnosis for those patients who present with symptoms spans the field of medicine. Biochemical case detection testing relies on measurement of fractionated metanephrines and catecholamines by tandem mass spectrometry or high-pressure liquid chromatography. The clinician should assess the relative likelihood of pheochromocytoma in each patient. Decisions for the type of test performed may be subject to clinical availability, cost, clinical experience of the ordering physician, and the local laboratory. However, it is key to understand the medications and clinical situations that may cause false-positive biochemical testing.",
keywords = "Catecholamines, Metanephrines, Paraganglioma, Pheochromocytoma",
author = "Young, {William Francis}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-3-319-77048-2_6",
language = "English (US)",
series = "Contemporary Endocrinology",
publisher = "Humana Press Inc.",
pages = "99--111",
booktitle = "Contemporary Endocrinology",

}

TY - CHAP

T1 - Diagnosis of pheochromocytoma and paraganglioma

AU - Young, William Francis

PY - 2018/1/1

Y1 - 2018/1/1

N2 - There has been a dramatic evolution in both the clinical presentation and the methods used to diagnose pheochromocytoma and paraganglioma (PPGL) over the past nine decades. Due to the advances in biochemical testing and cross-sectional computed imaging, we have progressed from prior to 1970 when 90% of patients with PPGL were detected because of symptoms (paroxysms or hypertension) to 2018 when 60% of patients with PPGL are diagnosed due to an incidental discovery on cross-sectional imaging done for other reasons. Thus, the clinician should recognize the imaging phenotype typical for a pheochromocytoma. The differential diagnosis for those patients who present with symptoms spans the field of medicine. Biochemical case detection testing relies on measurement of fractionated metanephrines and catecholamines by tandem mass spectrometry or high-pressure liquid chromatography. The clinician should assess the relative likelihood of pheochromocytoma in each patient. Decisions for the type of test performed may be subject to clinical availability, cost, clinical experience of the ordering physician, and the local laboratory. However, it is key to understand the medications and clinical situations that may cause false-positive biochemical testing.

AB - There has been a dramatic evolution in both the clinical presentation and the methods used to diagnose pheochromocytoma and paraganglioma (PPGL) over the past nine decades. Due to the advances in biochemical testing and cross-sectional computed imaging, we have progressed from prior to 1970 when 90% of patients with PPGL were detected because of symptoms (paroxysms or hypertension) to 2018 when 60% of patients with PPGL are diagnosed due to an incidental discovery on cross-sectional imaging done for other reasons. Thus, the clinician should recognize the imaging phenotype typical for a pheochromocytoma. The differential diagnosis for those patients who present with symptoms spans the field of medicine. Biochemical case detection testing relies on measurement of fractionated metanephrines and catecholamines by tandem mass spectrometry or high-pressure liquid chromatography. The clinician should assess the relative likelihood of pheochromocytoma in each patient. Decisions for the type of test performed may be subject to clinical availability, cost, clinical experience of the ordering physician, and the local laboratory. However, it is key to understand the medications and clinical situations that may cause false-positive biochemical testing.

KW - Catecholamines

KW - Metanephrines

KW - Paraganglioma

KW - Pheochromocytoma

UR - http://www.scopus.com/inward/record.url?scp=85064882527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064882527&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-77048-2_6

DO - 10.1007/978-3-319-77048-2_6

M3 - Chapter

T3 - Contemporary Endocrinology

SP - 99

EP - 111

BT - Contemporary Endocrinology

PB - Humana Press Inc.

ER -